These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26182825)

  • 1. Strategies for the safe use of colistin.
    Ortwine JK; Sutton JD; Kaye KS; Pogue JM
    Expert Rev Anti Infect Ther; 2015; 13(10):1237-47. PubMed ID: 26182825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin: new lessons on an old antibiotic.
    Yahav D; Farbman L; Leibovici L; Paul M
    Clin Microbiol Infect; 2012 Jan; 18(1):18-29. PubMed ID: 22168320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS; Karatza DC
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin: understanding and applying recent pharmacokinetic advances.
    Ortwine JK; Kaye KS; Li J; Pogue JM
    Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
    Falagas ME; Rafailidis PI; Ioannidou E; Alexiou VG; Matthaiou DK; Karageorgopoulos DE; Kapaskelis A; Nikita D; Michalopoulos A
    Int J Antimicrob Agents; 2010 Feb; 35(2):194-9. PubMed ID: 20006471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and risk factors of colistin-induced nephrotoxicity.
    Kim J; Lee KH; Yoo S; Pai H
    Int J Antimicrob Agents; 2009 Nov; 34(5):434-8. PubMed ID: 19726164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intravenous colistin in children.
    Kumar PP; Giri SR; Shaikh FA; Panigrahy N; Chirla D
    Indian Pediatr; 2015 Feb; 52(2):129-30. PubMed ID: 25691180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin Use in Neonates and Children With Infections Due to Carbapenem-resistant Bacteria.
    Antachopoulos C; Iosifidis E
    Pediatr Infect Dis J; 2017 Sep; 36(9):905-907. PubMed ID: 28650936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.
    Pogue JM; Ortwine JK; Kaye KS
    Clin Microbiol Infect; 2017 Apr; 23(4):229-233. PubMed ID: 28238870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin: Revival of an Old Polymyxin Antibiotic.
    Dijkmans AC; Wilms EB; Kamerling IM; Birkhoff W; Ortiz-Zacarías NV; van Nieuwkoop C; Verbrugh HA; Touw DJ
    Ther Drug Monit; 2015 Aug; 37(4):419-27. PubMed ID: 25549206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity of colistin: new insight into an old antibiotic.
    Falagas ME; Rafailidis PI
    Clin Infect Dis; 2009 Jun; 48(12):1729-31. PubMed ID: 19438398
    [No Abstract]   [Full Text] [Related]  

  • 18. [The revival of colistin: an old antibiotic for the 21st century].
    Nasnas R; Saliba G; Hallak P
    Pathol Biol (Paris); 2009 May; 57(3):229-35. PubMed ID: 18178335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?
    Ozsurekci Y; Aykac K; Cengiz AB; Bayhan C; Sancak B; Karadag Oncel E; Kara A; Ceyhan M
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):233-8. PubMed ID: 27041107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.